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Background:  The randomized PROTECT AF trial revealed that left atrial appendage (LAA) closure using a filter device (Watchman) was non-inferior 
to Warfarin for the primary endpoint of prophylaxis of stroke, systemic embolism and cardiovascular death in AF pts with CHADS2 ≥ 1. In PROTECT AF, 
patients were treated with Warfarin post-implant until a TEE demonstrated LAA closure (≤ 3mm of peri-device flow); Warfarin was then withdrawn and 
patients continued antiplatelet therapy alone. But this strategy is not possible in patients with contraindications to Warfarin. Herein, we report the 
initial results from the ASAP Registry, a multicenter registry of WATCHMAN implantation in patients with contraindications to Warfarin use.
Methods:  In AF patients with contraindications to Warfarin, the Watchman LAA closure device was implanted in standard fashion: IV heparinization, 
transseptal puncture, TEE guidance. Post-implantation, patients were discharged on life-long aspirin and 6 months of clopidigrel. Follow-up TEE was 
performed at 3 and 12 months to assess for LAA closure and device-associated thrombus.
Results:  A total of 90 pts were enrolled at 4 enrolling centers in Europe: age 71.9 ± 7.8 (53 -93), 30% female, congestive heart failure in 20%, 
hypertension in 89%, diabetes in 32%, prior stroke or transient ischemic attack (TIA) in 39%, Age ≥ 75 in 38%, CHADS2 score = 2.6 ± 1.1 (1 - 5). 
Successful implantation was achieved in 82/90 pts (91%). Currently, median follow-up is 6 months with 28 patients followed to one year. Two 
patients experienced an ischemic stroke; TEE revealed no thrombus on the surface of the device or in the LA. There were 2 other patients with 
device-related thrombus; 1 detected within 45 days of the procedure and 1 detected on 3 month TEE. Three procedure related safety events 
occurred; 1 pericardial tamponade, 1 device embolization requiring percutaneous retrieval and 1 pseudoaneurysm repair. Follow-up is ongoing.
Conclusion: This early multicenter experience reveals that Watchman implantation without Warfarin overlap is safely feasible in AF patients with 
contraindications to oral anticoagulation. LAA closure may be a viable alternative for AF patients with Warfarin contraindications.
